Literature DB >> 10549452

Acceptability of two spermicides in five countries.

E Raymond1, G Alvarado, L Ledesma, S Diaz, S Bassol, E Morales, V Fernandez, G Carlos.   

Abstract

Data from a large, international, multicenter, randomized trial were analyzed to compare the acceptability of two nonoxynol-9 spermicide preparations. Women who wished to use a spermicide for contraception were randomly assigned to use either a foaming tablet (n = 383) or a nonoxynol-9 film (n = 382) for 28 weeks as their only method of contraception. Participants completed questionnaires about acceptability of the assigned product 4 weeks after admission and at discontinuation. Women in both groups had very favorable opinions of the spermicide. The proportion of women who said that they liked their assigned product very much was 50% in the tablet group and 55% in the film group. Significantly more women in the film group rated the spermicide difficult to insert and stated that the product stuck to the finger during insertion. More women in the tablet group said that the product was messy and that, at least once, it did not dissolve. In both groups, liking the product was significantly associated with consistency of use, but not with subsequent pregnancy. Participants' male partners had little influence on participants' opinions about, or use of, the spermicides. Although previous analyses showed that both spermicides are associated with high pregnancy rates, they are both highly acceptable to most women.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Americas; Central America; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents; Contraceptive Methods; Contraceptive Usage; Developed Countries; Developing Countries; Ecuador; English Speaking Africa; Family Planning; Ghana; Guatemala; Latin America; Method Acceptability--women; Mexico; Nonoxynol-9; North America; Northern America; Research Methodology; Research Report; South America; Spermicidal Contraceptive Agents; United States; Vaginal Spermicides; Western Africa; Women

Mesh:

Substances:

Year:  1999        PMID: 10549452     DOI: 10.1016/s0010-7824(99)00060-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Acceptability of five nonoxynol-9 spermicides.

Authors:  Elizabeth G Raymond; Pai Lien Chen; Sean Condon; Joanne Luoto; Kurt T Barnhart; Mitchell D Creinin; Alfred Poindexter; Livia Wan; Mark Martens; Robert Schenken; Richard Blackwell
Journal:  Contraception       Date:  2005-06       Impact factor: 3.375

2.  Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).

Authors:  Jennifer A Robinson; Mark A Marzinke; Edward J Fuchs; Rahul P Bakshi; Hans M L Spiegel; Jenell S Coleman; Lisa C Rohan; Craig W Hendrix
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

3.  Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.

Authors:  Wei Zhang; Michael A Parniak; Stefan G Sarafianos; Marilyn R Cost; Lisa C Rohan
Journal:  Int J Pharm       Date:  2013-12-09       Impact factor: 5.875

4.  Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.

Authors:  Ayman Akil; Michael A Parniak; Charlene S Dezzuitti; Bernard J Moncla; Marilyn R Cost; Mingguang Li; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2011-06-01       Impact factor: 4.617

5.  A brief sexual barrier intervention for women living with AIDS: acceptability, use, and ethnicity.

Authors:  D L Jones; S M Weiss; R Malow; M Ishii; J Devieux; H Stanley; A Cassells; J N Tobin; E Brondolo; A LaPerriere; J Efantis-Potter; M J O'Sullivan; N Schneiderman
Journal:  J Urban Health       Date:  2001-12       Impact factor: 3.671

6.  Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).

Authors:  Jennifer A Robinson; Mark A Marzinke; Rahul P Bakshi; Edward J Fuchs; Christine L Radebaugh; Wutyi Aung; Hans M L Spiegel; Jenell S Coleman; Lisa C Rohan; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-13       Impact factor: 2.205

7.  Preferred Physical Characteristics of Vaginal Film Microbicides for HIV Prevention in Pittsburgh Women.

Authors:  Maria D Fan; Lindsay F Kramzer; Sharon L Hillier; Judy C Chang; Leslie A Meyn; Lisa C Rohan
Journal:  Arch Sex Behav       Date:  2016-08-29

8.  A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

Authors:  Katherine E Bunge; Charlene S Dezzutti; Lisa C Rohan; Craig W Hendrix; Mark A Marzinke; Nicola Richardson-Harman; Bernard J Moncla; Brid Devlin; Leslie A Meyn; Hans M L Spiegel; Sharon L Hillier
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

9.  Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV prevention.

Authors:  Tiantian Gong; Wei Zhang; Michael A Parniak; Phillip W Graebing; Bernard Moncla; Phalguni Gupta; Kerry M Empey; Lisa C Rohan
Journal:  J Pharm Innov       Date:  2017-03-03       Impact factor: 2.750

10.  Tideglusib, a prospective alternative to nonoxynol-9 contraceptive.

Authors:  Zhiting Chen; Niyan Shu; Yuzhu Wang; Yiting Yang; Zhiyu Shao; Fang Tian; Minjie Xia; Zhikai Wang; Xin Wang; Xing Feng; Xianliang Huang; Weihua Li; Heguo Yu; Hua Diao
Journal:  Contracept X       Date:  2019-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.